Literature DB >> 28820715

Limited Transmission Potential of Takeda's Tetravalent Dengue Vaccine Candidate by Aedes albopictus.

Elizabeth A Dietrich1, Yee Tsuey Ong1, Janae L Stovall1, Hansi Dean2, Claire Y-H Huang1.   

Abstract

Recombinant live-attenuated chimeric tetravalent dengue vaccine viruses, TDV-1, -2, -3, and -4, contain the premembrane and envelope genes of dengue virus serotypes 1-4 in the replicative background of the attenuated dengue virus type-2 (DENV-2) PDK-53 vaccine strain. Previous results have shown that these recombinant vaccine viruses demonstrate limited infection and dissemination in Aedes aegypti and are unlikely to be transmitted by the primary mosquito vector of DENVs. In this report, we expand this analysis by assessing vector competence of all four serotypes of the TDV virus in Aedes albopictus, the secondary mosquito vector of DENVs. Our results indicate that these vaccine viruses demonstrate incompetence or defective infection and dissemination in these mosquitoes and will likely not be transmissible.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28820715      PMCID: PMC5817759          DOI: 10.4269/ajtmh.17-0185

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  34 in total

1.  Dynamics of susceptibility and transmissibility of the live, attenuated, candidate vaccines dengue-1 PDK13, dengue-3 PGMK30F3, and dengue-4 PDK48 after oral infection in Aedes aegypti.

Authors:  N Jirakanjanakit; M M Khin; S Yoksan; N Bhamarapravati
Journal:  Am J Trop Med Hyg       Date:  1999-10       Impact factor: 2.345

2.  Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development.

Authors:  Claire Y-H Huang; Siritorn Butrapet; Kiyotaka R Tsuchiya; Natth Bhamarapravati; Duane J Gubler; Richard M Kinney
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

3.  Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53.

Authors:  R M Kinney; S Butrapet; G J Chang; K R Tsuchiya; J T Roehrig; N Bhamarapravati; D J Gubler
Journal:  Virology       Date:  1997-04-14       Impact factor: 3.616

4.  Wolbachia modulates Chikungunya replication in Aedes albopictus.

Authors:  L Mousson; E Martin; K Zouache; Y Madec; P Mavingui; A B Failloux
Journal:  Mol Ecol       Date:  2010-03-22       Impact factor: 6.185

5.  Limited potential for transmission of live dengue virus vaccine candidates by Aedes aegypti and Aedes albopictus.

Authors:  M R Sardelis; R Edelman; T A Klein; B L Innis; J R Putnak; J W Jones; M J Turell
Journal:  Am J Trop Med Hyg       Date:  2000-06       Impact factor: 2.345

6.  Infection, dissemination, transmission, and biological attributes of dengue-2 PDK53 candidate vaccine virus after oral infection in Aedes aegypti.

Authors:  M M Khin; N Jirakanjanakit; S Yoksan; N Bhamarapravati
Journal:  Am J Trop Med Hyg       Date:  1994-12       Impact factor: 2.345

Review 7.  Development of new vaccines against dengue fever and Japanese encephalitis.

Authors:  R M Kinney; C Y Huang
Journal:  Intervirology       Date:  2001       Impact factor: 1.763

8.  Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study.

Authors:  Richard Rupp; Gary Joseph Luckasen; Judith Lee Kirstein; Jorge E Osorio; Joseph D Santangelo; Marsha Raanan; Mary Kathryn Smith; Derek Wallace; Gilad S Gordon; Dan T Stinchcomb
Journal:  Vaccine       Date:  2015-09-15       Impact factor: 3.641

Review 9.  Consequences of the expanding global distribution of Aedes albopictus for dengue virus transmission.

Authors:  Louis Lambrechts; Thomas W Scott; Duane J Gubler
Journal:  PLoS Negl Trop Dis       Date:  2010-05-25

10.  The endosymbiotic bacterium Wolbachia induces resistance to dengue virus in Aedes aegypti.

Authors:  Guowu Bian; Yao Xu; Peng Lu; Yan Xie; Zhiyong Xi
Journal:  PLoS Pathog       Date:  2010-04-01       Impact factor: 6.823

View more
  2 in total

1.  Customers' preferences and willingness to pay for a future dengue vaccination: a study of the empirical evidence in Vietnam.

Authors:  Trung Quang Vo; Quang Vinh Tran; Nam Xuan Vo
Journal:  Patient Prefer Adherence       Date:  2018-11-27       Impact factor: 2.711

2.  Single dose of chimeric dengue-2/Zika vaccine candidate protects mice and non-human primates against Zika virus.

Authors:  Whitney R Baldwin; Holli A Giebler; Janae L Stovall; Ginger Young; Kelly J Bohning; Hansi J Dean; Jill A Livengood; Claire Y-H Huang
Journal:  Nat Commun       Date:  2021-12-16       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.